Leaflet LETROZOLE MYLAN 2.5mg tablets
Indicated for: breast cancer
Route of administration: oral
Substance: letrozole (aromatase inhibitor)
ATC: L02BG04 (Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Aromatase inhibitors)
This medicine may affect fertility.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
This medicine may affect fetal development.
Letrozole is an aromatase inhibitor used for the treatment of hormone-dependent breast cancer in postmenopausal women. It works by reducing estrogen levels, thereby inhibiting the growth of hormone-sensitive tumors.
The medication is taken orally, usually once daily, as directed by a doctor. It is important to follow the treatment regimen to achieve the best results.
Side effects may include hot flashes, fatigue, joint pain, or osteoporosis. In rare cases, allergic reactions or liver disorders may occur.
Letrozole is not recommended for pregnant or breastfeeding women or patients with hypersensitivity to this medication.
General data about LETROZOLE MYLAN 2.5mg
- Substance: letrozole
- Date of last drug list: 01-07-2013
- Commercial code: W54676001
- Concentration: 2.5mg
- Pharmaceutical form: tablets
- Quantity: 28
- Product type: generic
- Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.